Skip to content
Company Analysis

Haemonetics Corporation HAE

A comprehensive view of key metrics, scores, and financial health for Haemonetics Corporation

Overview of Haemonetics Corporation

HAE NYQ
Healthcare Medical Instruments & Supplies Mid Cap
Haemonetics Corporation (HAE), is a Mid Cap company, in the Medical Instruments & Supplies industry, last closed at $59.92, about 3.7% undervalued vs fair value, -7.5% 1Y return, placing in the top 10% of its sector.
$59.92
0.72%
As of March 13, 2026
Previous close • Vol 90d: 57.3%
52-Week Range
Market Cap
$2.80B
Enterprise Value
$3.67B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Haemonetics Corporation.

Top Beats

Quick Facts

Website https://www.haemonetics.com
HQ Boston, MA
Employees 3,023
Fiscal year Mar 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$56
$62
$69
Current: $59.92 +4% vs base

Engine Room Money Flow™

Mid Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$1.4B
4%%
Gross Profit
$749.0M
8.3%%
Operating Income
$201.2M
16.1%%
Net Income
$167.7M
42.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
85.0%
Good

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$232.0M
162.9% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
1/4
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Haemonetics Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
71
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
72
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing HAE's balance between Growth (33.2%), Profitability (36.2%), and Safety (30.6%). Growth 33% Safety 31% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

70th percentile vs peers
70
Key Signals
Revenue CAGR 3Y 11.1% 69p EPS Growth YoY 44.5% 75p Rev Growth YoY 4.0% 49p EPS CAGR 3Y 57.6% 94p TSR 31.1% 90p
Strengths
  • Eps Cagr 3Y in top 20% of peers (57.6%, 94th percentile)
  • D/E Ratio in top 20% of peers (1.49, 89th percentile)
  • Interest Coverage Ratio in top 20% of peers (22.76, 86th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

76th percentile vs peers
77
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

64th percentile vs peers
65
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Haemonetics Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$62.16
- - -
+3.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info